DDIT3 and cancer: Interestingly, as in the case of EVO, the treatment effect was reversible via inhibited CHOP expression preceded by the inhibition of p-PERK by GSK2606414, which may suggest a dual role of PERK in development of targeted anti-cancer therapy.